Having trouble accessing articles? Reset your cache.

Vectibix panitumumab: Phase III data

Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif.
Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan
Product: Vectibix panitumumab
Business: Cancer
Molecular target:

Read the full 210 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE